SNTI

Senti Biosciences Holdings, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001854270 Biotech & Drug Discovery

$0.1744 −0.01 (−7.23%)

Oct 26 4:00 PM ET · prev $0.1880

Market cap

$5.9M

Nano cap

Median target

$13.50

+7641% · range $12.00–15.00

Next earnings

Nov 9

in 14 days · EPS est. −$0.29

1 year

−92.2%

from $2.24 · Oct 27

30 days

−43.7%

from $0.3100

52-week range

$0.1744–2.39

at the low

Avg volume 20D

1.35M

Oct 15 spike 18.99M

Short interest

487.2K

≈1.6% of shares · −4.6%

Days to cover

1.0

at average volume

Insider net

no open-market trades · 12 mo

Filing reports

analyzed by SecBot

SecBot read BEARISH 9 reports · 90 days

Balance 7 bearish · 0 bullish · 2 mixed oldest → newest, height = score

Avg score

·High conf. 7/9 ·Next Earnings date, Nov 9, 2026

Strongest MIXED Senti Biosciences adjourned its 2026 Annual Meeting on October 8 without conducting business, despite a…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
EstimatesRISING

Current-quarter EPS estimate −$0.323 → −$0.295 over 90 days.
Short sellersSTEADY

Short interest −4.6% to 487.2K shares. 1.0 days to cover, ≈1.6% of shares.
TrendDOWNTREND

45% below its 50-day average. New closing low $0.1744 on Oct 26.

Who's buying

13F

Top holder	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	537,504	$591.3K
GEODE CAPITAL MANAGEMENT, LLC	187,065	$205.8K
CITADEL ADVISORS LLC	107,100	$117.8K
VANGUARD FIDUCIARY TRUST CO	91,193	$100.3K
JANE STREET GROUP, LLC	52,530	$57.8K
NORTHERN TRUST CORP	32,154	$35.4K
UBS Group AG	14,432	$15.9K
STATE STREET CORP	10,010	$11.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026

12-month targets · 2 analysts

$0.1744 $12.00 $13.50 $15.00

Price is below the lowest target. Median implies +7641%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
May 15, 2026	Chardan Capital MAINTAIN	MAINTAIN	Buy

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 9, 2026

Earnings date

SNTI Q3 2026 Earnings Scheduled — 2026-11-09

Recent

Sep 3, 2026

Listing

Listing Status: SNTI — Deficient (was Normal)

Senti Biosciences Holdings, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D

Aug 10, 2026

Earnings date

SNTI Q2 2026 Earnings Scheduled — 2026-08-10

Aug 3, 2026

Earnings date

SNTI Q2 2026 Earnings Scheduled — 2026-08-03

Jul 15, 2026

Trading halt

Halt Resumed: SNTI — trading resumed after T3 (News and Resumption Times)

Halted 2026-07-15T11:25:00.000Z | Resumed 2026-07-15T12:00:00.000Z

Jul 15, 2026

Trading halt

Trading Halt: SNTI — T3 (News and Resumption Times)

Senti Biosciences Hldgs Cmn | Market: NASDAQ | Code: T3 — News and Resumption Times

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Oct 21, 2026	Rajangam Kanya Pres. & Chief Med. & Dev. Off.	TAX W/H	19,953 sh
Oct 21, 2026	Lu Timothy K CEO	TAX W/H	157,312 sh
Mar 9, 2026	Rajangam Kanya Pres. & Chief Med. & Dev. Off.	TAX W/H	10,757 sh
Mar 9, 2026	Lu Timothy K CEO	TAX W/H	80,666 sh
Feb 2, 2026	Lu Timothy K CEO	TAX W/H	4,191 sh
Feb 2, 2026	Rajangam Kanya Pres. & Chief Med. & Dev. Off.	TAX W/H	1,384 sh

Earnings setup

Estimates

Nov 9

reports in 14 days

−$0.29

EPS estimate, this quarter

+9%

estimate change, 90 days

Current-quarter EPS estimate

−$0.323

90d

−$0.377

60d

−$0.377

30d

−$0.377

−$0.295

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.29	-$0.38–-$0.21	+21.7%	$0.00
Next Q	-$0.33	-$0.44–-$0.21	-17.5%	$0.00
Current FY	-$1.04	-$1.31–-$0.78	+9.7%	$50.0K
Next FY	-$0.95	-$0.96–-$0.94	+0.0%	$50.0K